The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Abstract
Purpose: Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies. Patients and Methods: Patients with advanced breast cancer were candidates to receive metronomic oral capecitabine (500 mg thrice daily) and cyclophosphamide (50 mg daily) plus bevacizumab (10 mg/kg every 2 weeks). Results: In 46 assessable patients, we observed one complete response (CR; 2%), 21 partial responses (PR; 46%), 19 patients (41%) with stable disease (SD), and five patients (11%) with progressive disease, for an overall response rate of 48% (95% CI, 33% to 63%). Additional long-term disease stabilization (SD ≥ 24 weeks) occurred in eight patients, for an overall clinical benefit (CR + PR + SD ≥ 24 weeks) of 68% (95% CI, 51% to 81%). Median time to progression was 42 weeks (95% CI, 26 to 72 weeks). Toxicity was generally mild. Grade 3 or 4 nonhematologic adverse effects included hypertension (n = 8), transaminitis (n = 2), and nausea/vomiting (n = 2). Higher baseline circulating endothelial cells (CECs) were correlated with overall response (P = .02), clinical benefit (P = .01), and improved progression-free survival (P = .04). Conclusion: Treatment with metronomic capecitabine and cyclophosphamide in combination with bevacizumab was effective in advanced breast cancer and was minimally toxic. The number of baseline CECs significantly correlated with response and outcome, therefore supporting further studies on this surrogate marker for the selection of patients to be candidates for antiangiogenic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575
Self-citationGarcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Self-citationBertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Self-citationBocci, G., Nicolaou, K. C., & Kerbel, R. S. (2002) · PubMed · Cited by 444
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Mancuso, P., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R. S., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4570 · Cited by 252
Self-citationMunoz, R., Man, S., Shaked, Y., Lee, C. R., Wong, J., Francia, G., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4411 · Cited by 230
Self-citationNorden-Zfoni, A., Desai, J., Manola, J., Beaudry, P., Force, J., Maki, R., Folkman, J., Bello, C., Baum, C., DePrimo, S. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0919 · Cited by 200
Colleoni, M., Orlando, L., Sanna, G., Rocca, A., Maisonneuve, P., Peruzzotti, G., Ghisini, R., Sandri, M. T., Zorzino, L., Nolè, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj066 · Cited by 186
Self-citationKeshgegian, A. A., & Cnaan, A. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.1.42 · Cited by 184
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
Glode, L. M., Barqawi, A., Crighton, F., Crawford, E. D., & Kerbel, R. (2003) · Cancer · doi:10.1002/cncr.11713 · Cited by 162
Beaudry, P., Force, J., Naumov, G. N., Wang, A., Baker, C. H., Ryan, A., Soker, S., Johnson, B. E., Folkman, J., & Heymach, J. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2271 · Cited by 158
du Manoir, J. M., Francia, G., Man, S., Mossoba, M. E., Medin, J. A., Viloria‐Petit, A., Hicklin, D. J., Emmenegger, U., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1109 · Cited by 151
Liang, Y., Brekken, R. A., & Hyder, S. M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01221 · Cited by 149
VOGT, T. M., Hafner, C. M., Bross, K., Bataille, F., Jauch, K., Berand, A., Landthaler, M., Andreesen, R., & Reichle, A. (2003) · Cancer · doi:10.1002/cncr.11775 · Cited by 146
Rahman, Z. U., Frye, D. K., Smith, T. L., Asmar, L., Theriault, R. L., Buzdar, A. U., & Hortobágyi, G. N. (1999) · Cancer · Cited by 133
Endo, M., Shinbori, N., Fukase, Y., Sawada, N., Ishikawa, T., Ishitsuka, H., & Tanaka, Y. (1999) · International Journal of Cancer · Cited by 128
Bcl-2 Acts in a Proangiogenic Signaling Pathway through Nuclear Factor-κB and CXC Chemokines
Karl, E., Warner, K. A., Zeitlin, B. D., Kaneko, T., Wurtzel, L., Jin, T., Chang, J., Wang, S., Wang, C.-Y., Strieter, R. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0140 · Cited by 111
Regulation of VEGF in the reproductive tract by sex-steroid hormones.
Hyder, S. M., & Stancel, G. M. (2000) · PubMed · doi:10.14670/hh-15.325 · Cited by 60
Spieth, K., Kaufmann, R., & Gille, J. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0678-9 · Cited by 55
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Wakeling, A. E., Nicholson, R. I., & Gee, J. M. W. (2001) · PubMed · Cited by 50
Cited by
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
Self-citationMetronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Mouse models of advanced spontaneous metastasis for experimental therapeutics
Francia, G., Cruz-Munoz, W., Man, S., Xu, P., & Kerbel, R. S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3001 · Cited by 374
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
Metadata
- Authors
- Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., Pietri, E., & Colleoni, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-20
- Volume
- 26
- Issue
- 30
- Pages
- 4899-4905
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1984750597
- Cited by
- 293
- References
- 29
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.